|
|
| NEUE FORSCHUNGSERGEBNISSE |
|
Meta-analysis of the benefits of self-monitoring of blood glucose on glycemic
control in type 2 diabetes patients: an update.
BACKGROUND: Our systematic review and meta-analysis of the benefit of
self-monitoring of blood glucose (SMBG) in improving glycemic control in type 2
diabetes was published in 2008. With the few studies that have emerged afterward,
we undertook subsequent meta-analysis of the available evidence to update the
results. METHODS: Clinical trials of SMBG were identified through electronic
searches (MEDLINE, EMBASE, and The Cochrane Library) up to and including June
2009. Studies were included if they met the following inclusion criteria: (1)
randomized controlled trial comparing SMBG versus non-SMBG in type 2 diabetes
patients not using insulin and (2) hemoglobin A1c (HbA(1c)) reported as an
outcome measure. The efficacy was estimated with the mean difference in the
changes of HbA(1c) from baseline to final assessment between the SMBG and the
non-SMBG groups. RESULTS: SMBG was effective in reducing HbA(1c) in
non-insulin-treated type 2 diabetes (pooled mean difference, -0.24%; 95%
confidence interval, -0.34% to -0.14%; P < 0.00001). Glycemic control
significantly improved among the subgroup of patients whose baseline HbA(1c) was
>or=8%. In contrast, no significant effect of SMBG was detected in patients who
had HbA(1c) <8%. CONCLUSIONS: The available evidence suggests the usefulness of
SMBG in improving glycemic control in non-insulin-treated type 2 diabetes as
demonstrated by the reduction of HbA(1c) levels. In particular, SMBG proved to be
useful in the subgroup of patients whose baseline HbA(1c) was >or=8%.
|
|
Autoren:
Poolsup, Nalinee
; Suksomboon, Naeti
; Rattanasookchit, Somying
|
Quelle:
Diabetes Technol Ther. 2009 Dec;11(12):775-84.
|
| Literaturrecherche: U.S.National Library of Medicine's PubMed®
|
|
|

|
| |
Aktuelles
| |
| |
Produkte
| |
| |
Video-Präsentation
|
|
|